An Open Letter to the Food and Drug Administration and Pharmaceutical Industry Concerning Drug Approval for Children With Inflammatory Bowel Disease.

IF 4.5 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Inflammatory Bowel Diseases Pub Date : 2024-12-05 DOI:10.1093/ibd/izae226

Jeffrey S Hyams, Harland S Winter, Andrew E Mulberg, Eric Zuckerman

引用次数: 0

查看原文本刊更多论文

就儿童炎症性肠病药物审批问题致食品药品管理局和制药业的公开信。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammatory Bowel Diseases 医学-胃肠肝病学

CiteScore

9.70

自引率

6.10%

发文量

462

审稿时长

1 months

期刊介绍： Inflammatory Bowel Diseases® supports the mission of the Crohn''s & Colitis Foundation by bringing the most impactful and cutting edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.